chevron_left
IMS 2023
adjust
1. Does Dexamethasone Cause Cataracts? | Rahul Banerjee, MD, FACP | IMS 2023 Video
bookmark_border
2. Immune Profiling and Cellular Therapies | Bruno Paiva, PHD | IMS 2023 Video
bookmark_border
3. The Origin of Multiple Myeloma | Leif Bergsagel, MD | IMS 2023 Video
bookmark_border
4. OPTIMISMM Trial for Myeloma | Meral Beksac, MD | IMS 2023 Video
bookmark_border
5. Benefits of Healthy Living, 7th Nursing & Allied Health Conference | Beth Faiman, PhD, CNP | IMS 2023 Video
bookmark_border
6. Treatment Options for Frail Patients at Early Relapse | Paul Richardson, MD | IMS 2023 Video
bookmark_border
7. Results of Life Coaching in Myeloma | Rahul Banerjee, MD, FACP | IMS 2023 Video
bookmark_border
8. Laboratory Assessment of Immune Functioning | Doctors Avigan and Ludwig | IMS 2023 Video
bookmark_border
9. Preventing and Monitoring Infections With Immune Therapies | Joshua Richter, MD | IMS 2023 Video
bookmark_border
10. Key Take Aways from IMS 2023 | Rafael Fonseca, MD | IMS 2023 Video
bookmark_border
11. Monoclonal Gammopathy of Unknown Significance | Urvi Shah, MD | IMS 2023 Video
bookmark_border
12. Managing Renal Failure | Efstathious Kastritis, MD | IMS 2023 Video
bookmark_border
13. Changes in Weight in Induction Therapy | Ross Firestone, MD, PhD | IMS 2023 Video
bookmark_border
14. Wearable Tech for Early Detection of CRS in CAR T-cell Therapy | Sridevi Rajeeve, MD | IMS 2023 Video
bookmark_border
15. IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023 Video
bookmark_border
16. Update from IMS on Novel Technologies in Multiple Myeloma | Gareth Morgan, MD, PhD | IMS 2023 Video
bookmark_border
17. Trends in 11;14 FISH Testing for Myeloma | Linda Baughn, PH.D. | IMS 2023 Video
bookmark_border
18. Update on Research | Urvi Shah, MD | IMS 2023 Video
bookmark_border
19. Malignancies after Tandem ASCT for those on Total Therapy Protocols | Samer Al’Hadidi, MD | IMS 2023 Video
bookmark_border
20. Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023 Video
bookmark_border
21. Immune Based Strategies to Improve Outcomes of Cellular Therapies | Rakesh Popat, PhD | IMS 2023 Video
bookmark_border
22. A Comparative Study of Disparities in Myeloma Treatment Access | Matthew Leblanc, PHD, RN | IMS 2023 Video
bookmark_border
23. Charting the Genetic Evolution of Myeloma Cells | Faith Davies, MD | IMS 2023 Video
bookmark_border
24. Study on Risk Stratification in Smoldering Myeloma Patients | Malin Hultcrantz, MD, PhD | IMS 2023 Video
bookmark_border
25. Update on Risk Stratification in MGUS and SMM | Doctors Callander and Beksac | IMS 2023 Video
bookmark_border
26. Individualizing Frontline Treatment to Get the Best Outcomes | Xavier Leleu, MD, PhD | IMS 2023 Video
bookmark_border
27. Optimizing Imaging in Multiple Myeloma | Jens Hillengass, MD | IMS 2023 Video
bookmark_border
28. Impact of Racial Disparities in Myeloma | Doctors Cole and Kumar | IMS 2023 Video
bookmark_border
29. Sustained MRD Negativity in Transplant Eligible Patients | Camila Guerrero, PhD | IMS 2023 Video
bookmark_border
30. Managing CART-Cell Therapy in the Real World | Yi Lin, MD, PhD | IMS 2023 Video
bookmark_border
31. Using a Single Cell Approach to Define Mechanisms of Progression | Irene Ghobrial, MD | IMS 2023 Video
bookmark_border
32. Results from the GMMG Concept Trial in Germany | Lisa Leypoldt, MD | IMS 2023 Video
bookmark_border
33. Managing Acute Immune Complications | Krina Patel, MD | IMS 2023 Video
bookmark_border
34. Nutrivention Trial Update | Urvi Shah, MD | IMS 2023 Video
bookmark_border
35. Serial MRD Assessments as a Surrogate for Long Term PFS | Frits van Rhee, MD | IMS 2023 Video
bookmark_border
36. Using IMIDS and PIs to Treat at First Relapse | Paul Richardson, MD | IMS 2023 Video
bookmark_border
37. Update on KRdB Clinical Trial at Levine Cancer Institute | Shebli Atrash, MD | IMS 2023 Video
bookmark_border